Aug 20, 2025 • Zacks Commentary
BULLISH
GRFS or NBIX: Which Is the Better Value Stock Right Now?
GRFS vs. NBIX: Which Stock Is the Better Value Option?
Aug 12, 2025 • Zacks Commentary
NEUTRAL
Xenon Q2 Loss Wider Than Expected, Pipeline Development in Focus
XENE's wider Q2 loss highlights its push toward late-stage epilepsy, depression, and bipolar disorder studies with azetukalner.
Aug 08, 2025 • GlobeNewswire
NEUTRAL
Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter and First Half 2025
Tokyo, Japan and Cambridge, UK, 8 August 2025 - Nxera Pharma ( "the Company" or "Nxera". TSE: 4565 ) provides an update on operational activities and reports its consolidated results for the second quarter and first half ended 30 June 2025. The full report can be found here.
Aug 05, 2025 • Motley Fool
SOMEWHAT-BULLISH
Neurocrine ( NBIX ) Q2 2025 Earnings Call Transcript
Image source: The Motley Fool.Wednesday, July 30, 2025 at 8:30 p.m. ETChief Executive Officer - Kyle J. GanoContinue reading ...
Aug 01, 2025 • Motley Fool
SOMEWHAT-BULLISH
Neurocrine ( NBIX ) Q2 Revenue Jumps 17%
Neurocrine Biosciences ( NASDAQ:NBIX ) , a neuroscience-focused biopharma company, delivered a standout earnings report for the second quarter of fiscal 2025, released on July 30, 2025. The report revealed substantial outperformance: Non-GAAP diluted earnings per share reached $1.65, topping ...
Jul 30, 2025 • Zacks Commentary
NEUTRAL
Neurocrine Biosciences ( NBIX ) Q2 Earnings and Revenues Beat Estimates
Neurocrine (NBIX) delivered earnings and revenue surprises of +8.16% and +5.72%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?